- Performs a 20-gene panel to identify activated B-cell and germinal center B-cell subtypes of diffuse large B-cell lymphomas using the NanoString platform under CLIA conditions in formalin-fixed paraffin-embedded samples.
- Includes sufficient basic consultation with a subject matter expert.
- Perform messenger RNA isolation and expression analysis specific to a 20-gene panel on formalin-fixed paraffin-embedded patient samples using the NanoString platform.
- This assay has been validated for clinical samples and allows for the identification of activated B-cell and germinal center B-cell subtypes of diffuse large B-cell lymphomas to enable assignment to a therapeutic regimen.
- Isolate total RNA from sections of formalin-fixed paraffin-embedded material with a minimum requirement of 62.5 ng to proceed with the assay.
- Perform all assays with internal negative and positive control RNAs, in addition to both activated B-cell and germinal center B-cell control RNAs.
- Generate a mRNA expression profile of each sample and control using a custom panel of capture probes and the NanoString lymphoma subtyping test.
- Classify samples as either activated B-cell or germinal center B-cell subtypes using an established predictor algorithm.
All operations will be performed in a CLIA environment, and the CLIA Molecular Diagnostics Laboratory will provide a final report with the results with interpretations and conclusions.
Find more details about the assignment to a therapeutic regimen in our scientific publication.